Moleculin Biotech
MBRX
MBRX
16 hedge funds and large institutions have $1.95M invested in Moleculin Biotech in 2017 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
Holders
16
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$238K | |
| 2 | +$137K | |
| 3 | +$110K | |
| 4 |
TSS
Two Sigma Securities
New York
|
+$98.9K |
| 5 |
Truist Financial
Charlotte,
North Carolina
|
+$93.4K |
Top Sellers
| 1 | -$117K | |
| 2 | -$21K | |
| 3 | -$20K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$20K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4K |